Enhancing Treatment Adherence in Pediatric Asthma With a Problem Solving Intervention
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00149487|
Recruitment Status : Unknown
Verified November 2006 by National Heart, Lung, and Blood Institute (NHLBI).
Recruitment status was: Active, not recruiting
First Posted : September 8, 2005
Last Update Posted : November 8, 2006
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Behavioral: Tailored Problem Solving Intervention Behavioral: Family Education Intervention||Not Applicable|
Children and adolescents who are unable to adhere to their medical regimen for the management of chronic illness present considerable challenges to health care providers and researchers. Pediatric asthma is a chronic illness where the consequences of non-adherence are particularly detrimental and widespread, especially among economically disadvantaged minority children and their families. Studies of intervention of asthma management are needed for this population.
The aim of the proposed study is to test the efficacy of a problem solving intervention that is tailored to the observed adherence behaviors and identified barriers to increasing adherence in African American children and adolescents with asthma, and their families. Patients are randomized to either a Tailored Problem Solving Intervention, or a control group who will receive Family Education Intervention. Duration of the intervention is four months.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Official Title:||Randomized Controlled Trial of Problem Solving Intervention to Enhance Treatment Adherence in Pediatric Asthma|
|Study Start Date :||January 2001|
- Adherence to medical treatment, based on electronic monitors (measured at Months 3, 6, 9, and 12)
- Asthma-related morbidity, including symptoms, pulmonary functioning, and health-related quality of life (measured at Months 3, 6, 9 and 12)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00149487
|United States, Ohio|
|Case Western Reserve University|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||Dennis Drotar, PhD||Case Western Reserve University|